Patient-specific tumor immunoglobulin idiotype antigen (Id)

The patient-specific tumor immunoglobulin idiotype antigen is a unique protein structure found on the surface of malignant B-cells, representing the variable regions of the clonal B-cell receptor (BCR) (PMID: 19805674). Because each B-cell malignancy arises from a single transformed clone, the idiotype (Id) serves as a true tumor-specific antigen (TSA) that is absent from healthy cells (National Cancer Institute). Therapeutic strategies, such as those used for the vaccine Dasiprotimut-T (BiovaxID), involve the isolation and production of this patient-specific protein to create a personalized immunotherapy (PMID: 21633171). These vaccines are typically conjugated to carrier proteins like Keyhole Limpet Hemocyanin (KLH) and administered with GM-CSF to enhance the immune response against the tumor (PubMed Central: PMC3103825). The goal is to induce both humoral and cellular immunity to eliminate residual cancer cells and prolong remission. However, the high cost of individualized production and the failure of several phase III trials to meet primary endpoints have limited its widespread clinical adoption (PMID: 21422444).

Other names

Tumor-specific idiotypeB-cell idiotypeClonal idiotypeImmunoglobulin variable region antigenPatient-specific idiotype

Active immunotherapy via induction of host humoral and cellular immune responses against tumor-specific clonal determinants.